Apr 24

Cell & Gene: NK Cell Therapies – How Artiva Biotherapeutics Leverages Its “Manufacturing First” Approach

Chris Horan, chief technical operations officer, Artiva Biotherapeutics discusses with Cell & Gene natural killer (NK) cell therapies and Artiva’s experiences and strategies with its candidate, AlloNK.

He answers the following questions:

  • Why do NK cell therapies hold promise in treating autoimmune disease?
  • What is the biggest technical/scientific challenge of developing NK-based therapies, and what has been Artiva’s experience addressing that challenge?
  • What are the best practices, or pitfalls to avoid, of cryopreservation?
  • How is Artiva approaching clinical trials of its NK cell-based candidate, since patients need multiple doses?
  • Can you tell us more about Artiva’s “manufacturing-first approach” and how it’s different from the traditional approach? How is Artiva approaching the closed process to minimize any variability?

Read the Q&A here.

Recent Posts

See All

Inside Precision Medicine: Asked & Answered with Artiva’s CMO Dr. Subhashis Banerjee

Inside Precision Medicine spoke with Artiva’s Chief Medical Officer, Dr. Subhashis Banerjee, about our clinical development approach for AlloNK® in autoimmune disease. In the Q&A, Dr. Banerjee outlines how we are advancing AlloNK® through a parallel trial strategy, conducting both a Phase 2a basket trial and an investigator-initiated study in the community setting. These trials...

Pharmaceutical Manufacturer Q&A: Artiva Allogeneic NK Cell Therapies for Treating Autoimmune Disease

In this interview with Pharmaceutical Manufacturer, Artiva CEO Fred Aslan, M.D., discusses the unique advantages of natural killer (NK) cell therapies and the company’s mission to bring scalable, off-the-shelf treatments to patients with autoimmune diseases. The Q&A explores how Artiva’s AlloNK® platform—comprising non-genetically modified, cryopreserved NK cells combined with disease-targeting monoclonal antibodies—could offer a more...

GEN: The Body’s Delta Force: Natural Killer Cells Re-Emerge

In a new feature published by GEN (Genetic Engineering & Biotechnology News), natural killer (NK) cells are in the spotlight showcasing their potential as the next generation of immunotherapies. This article explores how scientific and technological advances are helping cell therapy developers harness NK cells to expand the reach of cell therapy beyond oncology and...